
Erlocip 100 Tablet
Marketer
Cipla Ltd
Salt Composition
Erlotinib (100mg)
Overview Erlocip 100 Tablet
Erlocip 100mg tablets treat non-small cell lung and pancreatic cancers. Administer on an empty stomach, or one hour before or two hours after meals. Continue treatment as directed by your physician; duration depends on individual response. Follow your doctor's instructions precisely; incorrect usage or overdosage may cause severe adverse reactions. Benefits may take weeks or months to appear; don't discontinue without medical advice. Common side effects include nausea, vomiting, tiredness, skin rashes, and weight reduction. Severe diarrhea should be reported; increase fluid intake or seek medical attention. Photosensitivity is possible; wear protective clothing and sunscreen outdoors. Report mouth sores, vision changes, or breathing problems immediately. Liver function monitoring may be necessary. Inform your healthcare provider about all other medications you're taking, as interactions are possible. This medication is contraindicated during pregnancy and breastfeeding; reliable contraception is crucial for both partners. Smoking cessation is recommended, as it can interfere with treatment efficacy. Separate administration of antacids or other medications by at least two hours is advised.
Primary Ingredients of Erlocip 100 Tablet
The provided text is "undefined," therefore no rewriting is possible.
Uses of Erlocip 100 Tablet
Cancers of the pancreas and non-small-cell lung
Major Benefits of Erlocip 100 Tablet:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Erlocip 100 Tablet whole; avoid chewing, crushing, or breaking it. Administer on an empty stomach.
Common Side effects of Erlocip 100 Tablet:
- Abdominal pain
- Bone pain
- Breathlessness
- Constipation
- Cough
- Diarrhea
- Fatigue
- Fever
- Infection
- Muscle pain
- Nausea
- Rash
- Stomatitis (Inflammation of the mouth)
- Vomiting
- Weight loss
How to use Erlocip 100 Tablet:
Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment duration. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Administer Erlocip 100 Tablet on an empty stomach.
How Erlocip 100 Tablet works:
Erlocip 100mg tablets combat lung cancer by targeting epidermal growth factor receptors (EGFR). These receptors, present on the surface of lung cancer cells, regulate their growth. The drug's mechanism involves binding to EGFR, thereby blocking the cancer-promoting signals these receptors transmit, ultimately hindering tumor expansion.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Erlocip 100 Tablet may pose unknown risks. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Using Erlocip 100 Tablet during pregnancy poses a known risk to the fetus. Its use is contraindicated except in rare, life-threatening circumstances where potential benefits outweigh the clear dangers. Always seek medical advice before taking this medication.
Breast feedingCONSULT YOUR DOCTOR
The use of Erlocip 100 Tablet while breastfeeding is likely inadvisable. Available human data indicates a potential for the medication to transfer to breast milk, posing a risk to the infant.
DrivingCONSULT YOUR DOCTOR
Driving ability while taking Erlocip 100 Tablet is undetermined. Refrain from driving if concentration or reaction time is impaired.
KidneySAFE IF PRESCRIBED
Erlocip 100 Tablet can be used by patients with kidney disease without altering the dosage. However, its administration is contraindicated in individuals with severely impaired kidney function.
LiverCAUTION
Patients with hepatic impairment should use Erlocip 100 mg tablets cautiously. Dosage modification may be necessary. Physician consultation is advised.
What if you forget to take Erlocip 100 Tablet :
Omit any missed Erlocip 100 Tablet dose and resume your usual medication regimen. Avoid taking a double dose.
Facts to Know About Erlocip 100 Tablet
| Label | Value |
|---|---|
| Chemical Type | Quinazoline-based compound |
| Developing Habits | No. |
| Treatment Category | Cancer Medications |
